Comparing the effects of LSD, psilocybin, and DMT on consciousness in healthy individuals
Official title: Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)
Run by University Hospital, Basel, Switzerland · NCT06899334 · Data updated 2026-11-12
This study is testing how three different psychedelics—LSD, psilocybin, and DMT—affect people's consciousness to see how they compare in healthy individuals.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 25 Years and up |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Status | Recruiting |
| Started | April 1, 2025 |
| Main results expected | August 1, 2026 |
| Study ends | August 1, 2026 |
| Registry record updated | March 27, 2025 |
| Trial ID | NCT06899334 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy individuals aged 18-65 with a good understanding of the German language and no history of major psychiatric disorders.
✕Probably not a fit
Patients with chronic medical conditions or a history of psychiatric disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to compare the effects of three psychedelics—LSD, psilocybin, and DMT—on consciousness in healthy participants. By administering equivalent doses of each substance while standardizing the duration of effects with ketanserin, the researchers will evaluate the qualitative similarities and differences in the peak experiences induced by these hallucinogens. The study is designed to ensure blinding and control for pharmacokinetic differences, making it a unique direct comparison of these substances. Participants will undergo a series of assessments to measure the acute and subacute effects of each psychedelic.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of psychedelics and their therapeutic potential for treating psychiatric disorders.
How similar studies have gone: While there have been studies on LSD and psilocybin, this direct comparison with DMT is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Good understanding of the German language 2. Understanding of procedures and risks associated with the study 3. Willing to adhere to the protocol and signing of the consent form 4. Willing to refrain from the consumption of illicit psychoactive substances during the study 5. Willing not to operate heavy machinery within 48 h after administration of a study substance 6. Willing to use effective birth control throughout study participation 7. Body mass index 17 - 34.9 kg/m2 Exclusion Criteria: 1. Relevant chronic or acute medical condition 2. Current or previous major psychiatric disorder (e.g. psychotic disorder) 3. Psychotic disorder or bipolar disorder in first-degree relatives 4. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg) 5. Bradycardia (\< 45 bpm) 6. Prolonged QTc interval (males: \>450 ms, females: \>470 ms) 7. AV block II° (Mobitz type and Webckebach type) and III° 8. Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months 9. Pregnancy or current breastfeeding 10. Participation in another clinical trial (currently or within the last 30 days) 11. Use of medication that may interfere with the effects of the study medication 12. Tobacco smoking (\>10 cigarettes/day) 13. Excessive consumption of alcoholic beverages (\>15 drinks/week)
Where it's running
-
University Hospital
Basel, Switzerland Recruiting
Study contacts
- Principal investigator: Matthias E Liechti, Prof. Dr. MD — University Hospital, Basel, Switzerland
- Study coordinator: Matthias E Liechti, Prof. Dr. MD
- Email: matthias.liechti@usb.ch
- Phone: 61 328 68 68
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.